Camrelizumab salvage therapy for extrahepatic recurrent hepatocellular carcinoma with PD-L1 negativity in transplanted liver tissue
10.3760/cma.j.cn421203-20220414-00073
- VernacularTitle:卡瑞利珠单抗挽救性治疗移植肝组织PD-L1阴性肝外复发性肝癌
- Author:
Yinan DENG
1
;
Guoying WANG
;
Jianfeng WANG
;
Linda FAN
;
Yingcai ZHANG
;
Tong ZHANG
;
Xuhong YI
;
Jian ZHANG
;
Hua LI
;
Yang YANG
Author Information
1. 中山大学附属第三医院肝脏外科暨肝移植中心 中山大学器官移植研究所 广东省器官移植研究中心 广东省移植医学工程实验室 广东省重点肝脏疾病实验室，广州 510630
- Keywords:
Liver transplantation;
Hepatocellular carcinoma;
Camrelizumab
- From:
Chinese Journal of Organ Transplantation
2022;43(5):276-280
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the safety and efficacy of camrelizumab salvage therapy for extrahepatic recurrent hepatocellular carcinoma with PD-L1 negativity in transplanted liver tissue.Methods:From May 2020 to December 2020, retrospective analysis was performed for 3 cases of camrelizumab salvage therapy for extrahepatic recurrent hepatocellular carcinoma recipients with PD-L1 negative in transplanted liver tissue.Three recipients with extrahepatic recurrence progressed after first/second-line targeted drug therapy.Camrelizumab was given as salvage therapy after normal tissue of ransplanted liver was confirmed as negative for PD-L1 by immunohistochemistry.The safety and efficacy of treatment were observed by monitoring the changes in the levels of alanine aminotransferase, aspartate aminotransferase and bilirubin, the occurrence of complications and the outcome of treatment before and after dosing.Results:During a follow-up period of 1.5 to 15.5 months, no recipients showed acute rejection symptoms such as sharp elevations of transaminase and bilirubin.Headache ( n=1), vomiting ( n=1) and fatigue & hypertension ( n=1) became relieved after treatment.As of February 28, 2022, there were one survivor and two deaths.The fatal causes were tumor progression ( n=1) and thoracic aortic rupture due to esophageal perforation ( n=1). The survival time of recipients was (11-15.5) months and the progression-free survival time (4-6) months. Conclusions:For extrahepatic recurrent hepatocellular carcinoma with PD-L1-negative liver transplantation in normal liver tissue, camrelizumab salvage therapy can control tumor progression to a certain extent and prolong the survival time of recipients.
